News >

Frontline Osimertinib Approved in Japan for NSCLC

Jason M. Broderick @jasoncology
Published: Wednesday, Aug 22, 2018

Dave Fredrickson

Dave Fredrickson

The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved osimertinib (Tagrisso) for the frontline treatment of patients with inoperable or recurrent EGFR-positive non–small cell lung cancer (NSCLC), according to AstraZeneca, the manufacturer of the EGFR inhibitor.

mutation–positive NSCLC.
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113125. doi: 10.1056/NEJMoa1713137.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication